Hybridoma
ChemPartner’s Hybridoma group provides premium monoclonal antibody services based on our advanced hybridoma platform, which has been validated by more than 30 therapeutic projects and a large number of reagent mAb projects. A number of key technologies are integrated into this platform to ensure the success of mAb development for therapeutic candidates and a broad range of assay applications.To date, we have worked with more than 50 biotech and pharmaceutical companies and research institutes worldwide and deliver antibodies meeting the desired specifications successfully for their assays and product development. We are continuously improving our service platforms and expanding our capabilities in the demanding areas such as GPCR/ion-channel antibody and ADC antibody discovery.
